Exelixis Inc (NAS:EXEL)
$ 20.91 -0.32 (-1.51%) Market Cap: 6.09 Bil Enterprise Value: 5.42 Bil PE Ratio: 32.52 PB Ratio: 2.90 GF Score: 92/100

Exelixis Inc at JPMorgan Healthcare Conference Transcript

Jan 15, 2020 / 12:30AM GMT
Release Date Price: $20.4 (+3.79%)
Eric William Joseph
JP Morgan Chase & Co, Research Division - VP & Senior Analyst

All right, great. I'm Eric Joseph, one of the senior biotech analysts here at JPMorgan. And our next presenting company is Exelixis Pharmaceuticals. It's my pleasure to welcome CEO, Mike Morrissey, to tell us a little bit about the company.

Just as a reminder, the breakout Q&A for this meeting will be across the hall in the Georgian Room. With that, Mike?

Michael M. Morrissey
Exelixis, Inc. - CEO, President & Director

All right. Excellent. Thank you. All right, good afternoon, everybody. Thanks for sticking around late and hearing our story. I'll go through a pretty detailed deck this afternoon.

Before I start, I thought it'd be important to put the last few days and 2020 into context based on where we came in 2019 and before then. Last year, especially, was a year of, I would say, hyper focus on 2 issues: our weekly IMS script numbers every Friday; and then lots of questions about 9ER, the front-line pivotal trial of cabo and nivo versus

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot